Supplemental Appendix

Supplemental Table 1. Characteristics of participants who did and did not participate in the 12- week extension study.

Characteristic	**Extension Study Participants, N = 45**	**Study Non-Participants, *N* = 46 f**
Sex (female), n (%)	34 (75.6%)	40 (87.0%)
Race (white), n (%)	25 (55.6%)	22 (47.8%)
Ethnicity (Hispanic), n (%)	3 (6.7%)	4 (8.7%)
Age (years)	48.6 ± 12.3	48.4 ± 11.7
Height (cm)	169.4 ± 9.5	167.2 ± 8.0
Weight at Week 52 (kg)	98.1 ± 16.3	95.1 ± 22.5
BMI at Week 52 (kg/m^{2})	34.1 ± 4.7	34.0 ± 7.4
Week-52 weight loss (% lost) from week 1	-13.0 ± 7.0	-11.0 ± 9.6
Week-52 weight loss (kg) from week 1	-14.6 ± 8.1	-11.2 ± 10.0

Note. Values shown are the mean ± standard deviation, except as otherwise noted. † Characteristics of the 46 participants who completed the initial 1-year trial but did not participate in the 12-week extension study. An additional nine participants were lost to follow-up and did not complete the 52-week outcomes assessment. There were no significant differences between the groups on any measure.

Supplemental Table 2. Estimated mean percent change in body weight from week 65 to week 73 in the intention-to-treat population

	Liraglutide-placebo, *N* = 23	**Liraglutide-phentermine, *N* = 22**	***p* value**
Body weight (% change)	+0.3 (0.4)	+1.5 (0.4)	**0.021**
Body weight (kg)	+0.3 (0.4)	+1.6 (0.4)	0.018
Proportion with weight loss ≥ 5% of randomization weight, n (%)	1 (4.3%)	1 (4.5%)	0.988
Proportion who maintain previous weight loss (< 1 kg gain from randomization), n (%)	13 (56.5%)	15 (68.2%)	0.256

Data for body weight change (% change and kg) from week 65 to week 72 are estimated marginal means (± *SEM)* for the intention-to-treat population (*N* = 45), controlling for weight change during the initial 1-year trial. In analyses of the proportion of participants who achieved categorical weight losses, individuals who missed the week 73 assessment were considered not to have maintained the loss.

Supplemental Table 3. Adverse events with an incidence of 5% or more of participants in any treatment group and all serious adverse events occurring between week 65 and week 73.

Event	Liraglutide-placebo, *N* = 23		Liraglutide-phentermine, *N* = 22	
	N (%)	Events, N	N (%)	Events, N
All adverse events	5 (21.7%)	7	5 (22.7%)	5
Adverse events ≥5% in any treatment group	5 (21.7%)	6	2 (9.1%)	2
Upper respiratory infection	1 (4.3%)	1	2 (9.1%)	2
Gastroenteritis	2 (8.7%)	2	0	0
Urinary tract infection	2 (8.7%)	2	0	0
All serious adverse events	0	0	1 (4.5%)	2
Quadriplegic event	0	0	1 (4.5%)	1
Death	0	0	1 (4.5%)	1